Pharmaceuticals - Community Register

  

Community register of medicinal products for human use


AUTHORISED  

Product information

Invented name: Xoterna Breezhaler   
Auth. number : EU/1/13/863
INN : indacaterol/glycopyrronium bromide
ATC: Anatomical main group: R - Respiratory system
Therapeutic subgroup: R03 - Anti-asthmatics
Pharmacological subgroup: R03A - Adrenergics, inhalants
Chemical subgroup: R03AL - Adrenergics in combination with anticholinergics
Chemical substance: R03AL04 - Indacaterol and glycopyrronium bromide
(See WHO ATC Index)
Indication: Xoterna Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Marketing Authorisation Holder: Novartis Europharm Limited
Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
23/09/2013 Centralised - Authorisation EMEA/H/C/3755 (2013)6219 of 19/09/2013
23/01/2014 Centralised - Variation EMEA/H/C/3755/WS/482
27/05/2014 Centralised - Variation EMEA/H/C/3755/N/3
12/06/2014 Centralised - Variation EMEA/H/C/3755/N/4